Profusa, Inc. (PFSA)

NGM – Real vaqt narxi. Valyuta: USD

0.45

-0.03 (-7.09%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.47

+0.02 (5.43%)

Bozor oldidan: May 13, 2026, 8:45 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Profusa, Inc. (PFSA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Profusa, Inc. (PFSA)

Profusa Receives Favorable Nasdaq Listing Determination

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance

Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Videolar

No Data

Press-relizlar

Profusa Receives Favorable Nasdaq Listing Determination

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

Search stocks

Profusa, Inc. (PFSA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Profusa, Inc. (PFSA)

Profusa Receives Favorable Nasdaq Listing Determination

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance

Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Videolar

No Data

Press-relizlar

Profusa Receives Favorable Nasdaq Listing Determination

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering